Research Article |
Corresponding author: Ali Mohammed ( dr.alihussainmohammed@gmail.com ) Academic editor: Rumiana Simeonova
© 2024 Ali Mohammed, Laith Saleh Alkaaby, Nada Alshawi.
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Citation:
Mohammed A, Saleh Alkaaby L, Alshawi N (2024) The pharmacological and clinical aspects of using gentamicin in cardiac surgery. Pharmacia 71: 1-9. https://doi.org/10.3897/pharmacia.71.e124486
|
Surgical site infection (SSI) is a serious postoperative complication after cardiac surgery. The objective of this research is to examine the efficacy of administering gentamicin in minimizing the incidence of SSI while closely monitoring the therapeutic level of the drug. Prospective research included 50 Iraqi patients divided into two groups, 25 in each: Group 1 received a combination of flucloxacillin and ceftriaxone, while Group 2 received a combination of flucloxacillin and gentamicin 2 mg/kg of ideal body weight given before surgery, then 80 mg*3 for 48 hours after surgery. A total of five patients had an infection at the surgical site, with four patients in Group 1 and one patient in Group 2. Additionally, two patients in each group exhibited increased renal indices. Among the patients in Group 2, the highest concentration of gentamicin in the blood was ≤ 2.5 µg/ml for eight patients, while for 17 patients, the gentamicin concentration in the blood ranged from 3 to 4.4 µg/ml.
surgical site infection, cardiac surgery, prophylactic antibiotics, gentamicin, survival
Surgical site infections (SSIs) are defined as infections that arise during the first 30 days after a surgical procedure or within 1 year after introducing foreign material into the body (
The optimum period of antimicrobial prophylaxis after cardiothoracic surgeries is a subject of debate. However, it is generally recommended that prophylaxis be administered during the surgery and for fewer than 24 hours thereafter (
For the prevention of SSI, it is recommended to provide cephalosporins within 60 minutes after making the surgical incision. The primary objective of the rules about the appropriate timing of antibiotics is to ensure that sufficient levels of the medication are present in the bloodstream and tissues, above the minimum inhibitory concentration required to effectively combat the bacteria, hence reducing the risk of surgical site infections (
Remarkably, there has been little research that has directly examined the effectiveness of gentamicin and cephalosporins (
Gentamicin is an aminoglycoside antibiotic that exhibits a wide range of antibacterial effects, mostly targeting Gram-negative bacteria, while its effectiveness against Gram-positive organisms is comparatively weaker. Gentamicin has significant efficacy against multidrug-resistant bacteria as well. Gentamicin is often used in conjunction with beta-lactam antibiotics to provide enhanced therapeutic efficacy via a synergistic effect, particularly in cases of gram-positive and multidrug-resistant bacterial infections (
A straightforward diagnostic method for infection is the assessment of body temperature. Another easy and cost-effective diagnostic approach is the assessment of the peripheral white blood cell (WBC) count and the differential cell count. There is a suggestion that the WBC and differential counts might be helpful in predicting bacterial infection. In addition, toxic granulations and vacuolization in the peripheral blood smear have been proposed as indicators of bacterial infection (
This study aims to evaluate the efficacy of administering gentamicin in combination with flucloxacillin as a pre-medication and for 48 hours after surgery in reducing the incidence of surgical site infections in patients undergoing cardiac surgeries, as compared to using a combination of ceftriaxone and flucloxacillin. Additionally, the study aimed to observe the therapeutic level of gentamicin required to achieve an effective concentration of the drug.
A prospective comparative study was conducted using an appropriate sample of 50 Iraqi patients who had undergone several types of cardiac surgeries. All patients underwent various types of cardiac surgery, such as coronary artery bypass graft (CABG), valve replacement, or device placement. The same surgical and anesthesia teams conducted the procedures.
A total of 50 patients (34 males and 16 females) were included in this study. These patients were admitted to the Surgical Department of the Iraqi Center for Heart Disease over a one-year period from January 2020 to January 2021.
The trial registration number is NCT06454643 and could be accessed at https://clinicaltrials.gov/.
A computerized randomization method was used to allocate patients into two groups in a randomized manner. Following the first interview, the patients were sequentially assigned numbers and then randomized into two groups via the online program Research Randomizer, as seen in Fig.
The total number of participants was determined using G*Power software (RRID: SCR 013726), version 3.1.9.7. To achieve a 95% confidence interval, 90% power, a one-tailed alpha of 0.05, and an effect size of 0.46, the required sample size is 50 individuals.
The research included individuals of both sexes, aged 18 and above, who had undergone any type of cardiac surgery. The participant underwent different types of cardiac surgeries, including atrial septal defect (ASD) closure, aortic valve replacement (AVR), coronary artery bypass graft surgery (CABG), mitral valve replacement (MVR), cor-triatriatum closure, double valve replacement (DVR), right atrial myxoma (RAM), and ventricular septal defect (VSD) closure.
Patients having a prior diagnosis of organ failure, patients already on antibiotics, patients with elevated baseline renal function tests before operation, or patients with contraindications to any of the prescribed medications were excluded from this study.
Patients were divided into 2 groups as follows:
The nursing staff in the ward gave the antibiotics according to the prescriptions in the patients’ files.
Patients were followed for a duration of 5 days post-surgery. The diagnosis of postoperative infection relies on the clinical assessment conducted by a physician and the analysis of laboratory data, including WBCs, hemoglobin level (Hb), erythrocyte sedimentation rate (ESR), chest x-ray, and body temperature. Furthermore, left ventricular ejection fraction (LVEF), the average cardiopulmonary bypass (CPB) duration, and the average aortic cross-clamp (ACC) time were also documented for both groups.
The therapeutic drug monitoring (TDM) Unit conducted serum level monitoring of gentamicin using the Architect gentamicin kit (reference code 1P31-25) and the Architect i1000SR instrument (Abbott Laboratories). The assay employed a two-step immunoassay known as the Chemiflux method, which utilized CIMA technology for the quantitative determination of gentamicin in serum or plasma. In addition, the laboratory renal indices of all patients were monitored to assess the risk of gentamicin nephrotoxicity. This was done by measuring the maximum levels of serum creatinine and urea on the day of the operation, as well as on days 3 and 5 after the operation. The definition of acute kidney injury, as per the kidney disease: Improving Global Outcome (KDIGO) guideline, was considered to be an increase in serum creatinine to 1.5 times the baseline level or higher (
A blood sample is obtained using conventional venipuncture methods, which involve drawing 2 ml of blood into silicone-coated plastic tubes with gel barriers. The anticoagulant that was used was EDTA. Ensure that the centrifuge process is sufficient to eliminate platelets. Follow the tube manufacturer’s directions to centrifuge the sample, ensuring the plasma is separated from the blood cells correctly. Samples that have been divided are kept for a maximum of 7 days at a temperature range of 2 to 8 °C before undergoing testing. The test relies on the competition between the drug in the sample and the drug in a small particle to attach to the antibody sites of the gentamicin antibody reagent, which is coated on paramagnetic microparticles. This is achieved by combining the gentamicin-acridinium-labeled conjugate with the sample to create a reaction mixture. The microparticles coated with an anti-gentamicin substance adhere to both the gentamicin found in the sample and the acridinium-labeled conjugate. After washing, the pre-trigger and trigger solutions are introduced into the reaction mixture. The chemiluminescent reaction’s outcome is quantified in terms of relative light units (RLUs). An inverse correlation exists between the quantity of gentamicin present in the sample and the RLUs identified by the optics of the Architect i System. The maximum concentration of gentamicin was detected within 30–60 minutes after administering the third dosage of the medicine.
The authors used rigorous measures to ensure that every eligible candidate had an equitable opportunity to be selected. Furthermore, the research was conducted to account for the specific settings, data accuracy, and quality assessment in order to minimize bias during the selection of the sample and the study methodology. This was achieved by utilizing a computer-based random number generator to generate an acceptable allocation sequence.
The data collection process employed Microsoft Office Excel 2019, while the acquired data were analyzed using SPSS 23 to compute the mean ± SD, ranges, frequencies, and ratios. The P-value was calculated using the chi-square statistic, T-test, and two-table contingency table analysis methods. A significance threshold of 0.05 or below was used to ascertain the statistical significance of all the data provided in this study. The data was graphically presented using GraphPad Prism 8.2 on Microsoft Windows.
The research included a total of 50 patients, with 25 patients in each group. Table
Demographic characteristics | Group 1 (n = 25) | Group 2 (n = 25) | P-value |
---|---|---|---|
Age | 47.7 ± 17.347 | 51.6 ± 13.61 | 0.073 |
Gender | Male: 18 (72%) Female: 7 (28%) | Male: 16 (64%) Female: 9 (36%) | 0.762 |
BMI | 26.7 ± 5.0 | 28.0 ± 4.79 | 0.334 |
DM | 8 (32%) | 5 (20%) | 0.333 |
CPB time (minutes) | 100.52 | 109.22 | 0.154 |
ACC time (minutes) | 77.08 | 70.72 | 0.323 |
LVEF ≤40% | 1 | 1 | 0.921 |
Group 1 consisted of 18 male patients (72%) and 7 female patients (28%), whereas Group 2 consisted of 16 male patients (64%) and 9 female patients (36%). In addition, the average age of patients in Group 1 was 47.76 ± 17.34 years, whereas in Group 2, it was 51.60 ± 13.61 years. In addition, 32% of patients in Group 1 were diagnosed with DM, whereas 25% of patients in Group 2 had this metabolic condition (P-value 0.333). Participants from both groups underwent different types of cardiac surgeries including atrial septal defect (ASD) closure, aortic valve replacement (AVR), coronary artery bypass graft surgery (CABG), mitral valve replacement (MVR), cor-triatriatum closure, double valve replacement (DVR), right atrial myxoma (RAM), ventricular septal defect (VSD) closure. Furthermore, it was observed that just one patient in each group had a left ventricular ejection fraction (LVEF) below 40% (P-value = 0.92). In Group 1, the average cardiopulmonary bypass (CPB) duration is 100.52 minutes, whereas in Group 2, it is 109.22 minutes (p-value = 0.154). Additionally, the average aortic cross-clamp (ACC) time is 77.08 minutes in Group 2 and 70.72 minutes in Group 2 (p-value 0.323).
There was no significant difference (P-value 0.349) in the incidence of infection between Group 1 and Group 2. In Group 1, 16% of patients (4 out of 25) had an infection, while in Group 2, 4% of patients (1 out of 25) developed an infection. Additionally, both groups had the same number of patients with increased renal indices (2 patients in each group).
On the fifth day after the operation, there was no significant difference (P > 0.05) in the average white blood cell count between Group 1 (12.56 ± 4.87) and Group 2 (11.32 ± 2.4). Similarly, there was no significant difference (P > 0.05) in the average erythrocyte sedimentation rate between Group 1 (64.9 ± 29) and Group 2 (63.16 ± 18.9). Additionally, there was no significant difference (P > 0.05) in the average of hemoglobin level between Group 1 (10.89 ± 1.26 mg/dl) and Group 2 (11.12 ± 0.71 mg/dl), as indicated in Figs
Changes in mean WBCs through baseline, day 1, day 3 and day 5 postoperatively in the studied patients’ groups. (G1B = group 1 at baseline, G1D1 = group 1 at day 1, G1D3 = group 1 at day 3, G1D5 = group 1 at day 5, G2B = group 2 at baseline, G2D1 = group 2 at day 1, G2D3 = group 2 at day 3, G2D5 = group 2 at day 5). A T-test was employed in the statistical analysis.
Changes in mean ESR through baseline, day 1, day 3 and day 5 postoperatively in the studied patients’ groups. (G1B = group 1 at baseline, G1D1 = group 1 at day 1, G1D3 = group 1 at day 3, G1D5 = group 1 at day 5, G2B = group 2 at baseline, G2D1 = group 2 at day 1, G2D3 = group 2 at day 3, G2D5 = group 2 at day 5). T-test was employed in the statistical analysis.
Changes in the mean Hb through baseline, day 1, day 3 and day 5 postoperatively in the studied patients’ groups. (G1B = group 1 at baseline, G1D1 = group 1 at day 1, G1D3 = group 1 at day 3, G1D5 = group 1 at day 5, G2B = group 2 at baseline, G2D1 = group 2 at day 1, G2D3 = group 2 at day 3, G2D5 = group 2 at day 5). A T-test was employed in the statistical analysis.
Group 2 patients were assessed for the peak level of gentamicin concentration. In Table
The combination of systemic hypothermia, coagulopathy accompanied by bleeding and the need for transfusions can make patients performing cardiac surgery more susceptible to infection (
The incidence of increased renal indices was comparable in both groups 1 and 2. The findings indicated that the flucloxacillin-gentamicin regimen (Group 2) resulted in a reduced rate of surgical site infections without any increase in the occurrence of renal damage. The decreased likelihood of acute renal impairment in a gentamicin-based treatment regimen may be attributed to enhanced defense against perioperative infection, a well-documented factor in the development of acute kidney damage. While our research did not demonstrate statistical significance, it is conceivable that it has clinical significance. The Scottish government set a goal in 2009 to decrease the incidence of Clostridium difficile infection by 30% over a period of 2 years. As a result, Scottish hospitals switched from using cephalosporins to gentamicin for surgical antibiotic prophylaxis. They investigated the incidence of postoperative acute renal damage before and after implementing this policy modification. The research sample consisted of 12,482 adult individuals who underwent surgical procedures. The modification in antibiotic policy did not result in a substantial rise in acute renal damage among the studied groups (
The number of white blood cells increased in all patients in groups 1 and 2 starting from the first day after the operations. The count reached its highest level on the third day and then decreased on the fifth day. This increase and subsequent decrease are a characteristic feature of the initial systemic inflammatory and stress response that occurs following heart surgery (
In the present study, peak gentamicin levels were measured for all patients in group 2. Among these patients, 38.5% had concentrations below 3 µg/ml, 61.5% had concentrations ranging from 3 µg/ml to less than 4.5 µg/ml, and none of the patients had concentrations equal to or more than 4.5 µg/ml. Another study has demonstrated that the highest level of gentamicin in the bloodstream is between 3 and 4 µg/ml. This concentration is sufficient when combined with penicillins to effectively treat infective endocarditis. These findings emphasize the importance of therapeutic drug monitoring to ensure that gentamicin reaches the necessary therapeutic concentration, particularly in cases of severe infection (
This study is one of the largest studies on SSI in cardiac surgery and, more specifically, on the use of gentamicin. The inclusion of patients and their surgical management were stable over time. Thus, the SSI rate was stable throughout the study.
This research was conducted during the time of the COVID-19 pandemic, which posed challenges in patient care and data gathering. Additionally, the surgical unit was temporarily closed for many months. This research pertains to a regional database from a single institution. It is probable that the selection of patients, choice of treatment, and care during the perioperative phase are significant factors that influence SSI. Furthermore, these parameters may differ across various cardiac surgery units. The research has a limited sample size. The duration of the follow-up period was limited to a short duration.
A short course of flucloxacillin in combination with gentamicin as antibiotic prophylaxis was shown to be as effective as a cephalosporin regimen in avoiding infection after heart surgery. The regular administration of a small dose of gentamicin did not result in a higher occurrence of acute kidney impairment.
The authors have declared that no competing interests exist.
The authors have no funding to report.
The scientific and ethical committees of Iraqi Board of Medical Specializations officially accepted the study protocol on 8/9/2019 with approval number 1420.
Before recruiting each individual, the researcher explained the study’s goal and got written consent.
Further data is available from the authors upon reasonable request. Trial registration: NCT06454643 at https://clinicaltrials.gov/.
Reporting Item | Page Number | ||
---|---|---|---|
Title and Abstract | |||
Title | #1a | Identification as a randomized trial in the title. | 1 |
Abstract | #1b | Structured summary of trial design, methods, results, and conclusions | 1 |
Introduction | 1 | ||
Background and objectives | #2a | Scientific background and explanation of rationale | 1,2 |
Background and objectives | #2b | Specific objectives or hypothesis | 1,2 |
Methods | 3 | ||
Trial design | #3a | Description of trial design (such as parallel, factorial) including allocation ratio. | 3 |
Trial design | #3b | Important changes to methods after trial commencement (such as eligibility criteria), with reasons | 3 |
Participants | #4a | Eligibility criteria for participants | 4 |
Participants | #4b | Settings and locations where the data were collected | 4 |
Interventions | #5 | The experimental and control interventions for each group with sufficient details to allow replication, including how and when they were actually administered | 4 |
Outcomes | #6a | Completely defined prespecified primary and secondary outcome measures, including how and when they were assessed | 5 |
Outcomes | #6b | Any changes to trial outcomes after the trial commenced, with reasons | 6 |
Sample size | #7a | How sample size was determined. | 6 |
Sample size | #7b | When applicable, explanation of any interim analyses and stopping guidelines | 6 |
Randomization - Sequence generation | #8a | Method used to generate the random allocation sequence. | |
Randomization - Sequence generation | #8b | Type of randomization; details of any restriction (such as blocking and block size) | |
Randomization - Allocation concealment mechanism | #9 | Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned | 3 |
Randomization - Implementation | #10 | Who generated the allocation sequence, who enrolled participants, and who assigned participants to interventions | 3 |
Blinding | #11a | If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how. | 3 |
Blinding | #11b | If relevant, description of the similarity of interventions | 3 |
Statistical methods | #12a | Statistical methods used to compare groups for primary and secondary outcomes | 6 |
Statistical methods | #12b | Methods for additional analyses, such as subgroup analyses and adjusted analyses | 6 |
Results | 6 | ||
Participant flow diagram (strongly recommended) | #13a | For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analyzed for the primary outcome | 6 |
Participant flow | #13b | For each group, losses and exclusions after randomization, together with reason | 6 |
Recruitment | #14a | Dates defining the periods of recruitment and follow-up | 6 |
Recruitment | #14b | Why the trial ended or was stopped | 6 |
Baseline data | #15 | A table showing baseline demographic and clinical characteristics for each group | |
Numbers analyzed | #16 | For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups | 6 |
Outcomes and estimation | #17a | For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval) | 7 |
Outcomes and estimation | #17b | For binary outcomes, presentation of both absolute and relative effect sizes is recommended | 7–10 |
Ancillary analyses | #18 | Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory | 7–10 |
Harms | #19 | All-important harms or unintended effects in each group (For specific guidance see CONSORT for harms) | |
Discussion | 11 | ||
Limitations | #20 | Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses | 12 |
Generalizability | #21 | Generalizability (external validity, applicability) of the trial findings | 12 |
Interpretation | #22 | Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence | 12 |
Registration | #23 | Registration number and name of trial registry | 12 |
Other information | |||
Interpretation | #22 | Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence | |
Registration | #23 | Registration number and name of trial registry | |
Protocol | #24 | Where the full trial protocol can be accessed, if available | |
Funding | #25 | Sources of funding and other support (such as supply of drugs), role of funders | 12 |